全文获取类型
收费全文 | 240篇 |
免费 | 29篇 |
国内免费 | 7篇 |
专业分类
儿科学 | 11篇 |
妇产科学 | 5篇 |
基础医学 | 83篇 |
口腔科学 | 1篇 |
临床医学 | 19篇 |
内科学 | 45篇 |
神经病学 | 8篇 |
特种医学 | 3篇 |
外科学 | 16篇 |
综合类 | 12篇 |
预防医学 | 5篇 |
眼科学 | 1篇 |
药学 | 30篇 |
中国医学 | 23篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 4篇 |
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 6篇 |
2019年 | 13篇 |
2018年 | 11篇 |
2017年 | 11篇 |
2016年 | 6篇 |
2015年 | 10篇 |
2014年 | 19篇 |
2013年 | 19篇 |
2012年 | 13篇 |
2011年 | 13篇 |
2010年 | 12篇 |
2009年 | 13篇 |
2008年 | 7篇 |
2007年 | 11篇 |
2006年 | 16篇 |
2005年 | 19篇 |
2004年 | 9篇 |
2003年 | 10篇 |
2002年 | 6篇 |
2001年 | 12篇 |
2000年 | 4篇 |
1999年 | 4篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1980年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有276条查询结果,搜索用时 31 毫秒
1.
BackgroundAutoimmune hepatitis is a chronic inflammatory disease, the abnormal immunological function is the main pathogenesis. Interleukin-34 is a newly identified cytokine that shares the same receptor as colony stimulating factor-1.MethodsWe used interleukin-34 knockout and wild-type mice in a Con A-induced hepatitis model and cocultured RAW264.7 macrophage cells with interleukin-34. We then detected associated inflammatory cytokine and chemokine levels to elucidate the role of interleukin-34.ResultsIn this study, we found that the loss of interleukin-34 resulted in higher sensitivity to Con A-induced hepatitis. RAW264.7 macrophage cells were able to differentiate to the M2 phenotype upon interleukin-34 stimulation.ConclusionsWe conclude that interleukin-34 may protect the liver from Con A-mediated hepatitis by driving M2 macrophage polarization and suppressing inflammation. 相似文献
2.
3.
Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine
Li-Zhen He Jeffrey Weidlick Crystal Sisson Henry C Marsh Tibor Keler 《Cellular & molecular immunology》2015,12(6):719-728
Previous studies have documented that selective delivery of protein antigens to cells expressing mannose receptor (MR) can lead to enhanced immune responses. We postulated that agents that influenced the MR expression level, and the activation and migration status of MR-expressing antigen presenting cells, would modulate immune responses to MR-targeted vaccines. To address this question, we investigated the effect of clinically used adjuvants in human MR transgenic (hMR-Tg) mice immunized with an MR-targeting cancer vaccine composed of the human anti-MR monoclonal antibody B11 fused with the oncofetal protein, human chorionic gonadotropin beta chain (hCGβ), and referred to as B11-hCGβ. We found that humoral responses to low doses of B11-hCGβ could be enhanced by prior administration of GM-CSF, which upregulated MR expression in vivo. However, co-administration of the Toll-like receptor (TLR) agonists, poly-ICLC and/or CpG with B11-hCGβ was required to elicit Th1 immunity, as measured by antigen-specific T-cell production of IFN-γ. The TLR agonists were shown to increase the number of vaccine-containing cells in the draining lymph nodes of immunized hMR-Tg mice. In particular, with B11-hCGβ and poly-ICLC, a dramatic increase in vaccine-positive cells was observed in the T-cell areas of the lymph nodes, compared to the vaccine alone or combined with GM-CSF. Importantly, the absence of the TLR agonists during the priming immunization led to antigen-specific tolerance. Therefore, this study provides insight into the mechanisms by which adjuvants can augment immune responses to B11-hCGβ and have implications for the rationale design of clinical studies combining MR-targeted vaccination with TLR agonists. 相似文献
4.
5.
6.
Ha T. Huynh Jeffrey H. Grubb Carole Vogler William S. Sly 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(42):17022-17027
Enzyme replacement therapy has been used successfully in many lysosomal storage diseases. However, correction of brain storage has been limited by the inability of infused enzyme to cross the blood–brain barrier (BBB). We recently reported that PerT-GUS, a form of β-glucuronidase (GUS) chemically modified to eliminate its uptake and clearance by carbohydrate-dependent receptors, crossed the BBB and cleared neuronal storage in an immunotolerant model of murine mucopolysaccharidosis (MPS) type VII. In this respect, the chemically modified enzyme was superior to native β-glucuronidase. Chemically modified enzyme was also delivered more effectively to heart, kidney, and muscle. However, liver and spleen, which express high levels of carbohydrate receptors, received nearly fourfold lower levels of PerT-GUS compared with native GUS. A recent report on PerT-treated sulfamidase in murine MPS IIIA confirmed enhanced delivery to other tissues but failed to observe clearance of storage in neurons. To confirm and extend our original observations, we compared the efficacy of 12 weekly i.v. infusions of PerT-GUS versus native GUS on (i) delivery of enzyme to brain; (ii) improvement in histopathology; and (iii) correction of secondary elevations of other lysosomal enzymes. Such correction is a recognized biomarker for correction of neuronal storage. PerT-GUS was superior to native GUS in all three categories. These results provide additional evidence that long-circulating enzyme, chemically modified to escape carbohydrate-mediated clearance, may offer advantages in treating MPS VII. The relevance of this approach to treat other lysosomal storage diseases that affect brain awaits confirmation. 相似文献
7.
CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages 总被引:1,自引:0,他引:1
Tiemessen MM Jagger AL Evans HG van Herwijnen MJ John S Taams LS 《Proceedings of the National Academy of Sciences of the United States of America》2007,104(49):19446-19451
CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) are potent suppressors of the adaptive immune system, but their effects on innate immune cells are less well known. Here we demonstrate a previously uncharacterized function of Tregs, namely their ability to steer monocyte differentiation toward alternatively activated macrophages (AAM). AAM are cells with strong antiinflammatory potential involved in immune regulation, tissue remodeling, parasite killing, and tumor promotion. We show that, after coculture with Tregs, monocytes/macrophages display typical features of AAM, including up-regulated expression of CD206 (macrophage mannose receptor) and CD163 (hemoglobin scavenger receptor), an increased production of CCL18, and an enhanced phagocytic capacity. In addition, the monocytes/macrophages have reduced expression of HLA-DR and a strongly reduced capacity to respond to LPS in terms of proinflammatory mediator production (IL-1beta, IL-6, IL-8, MIP-1alpha, TNF-alpha), NFkappaB activation, and tyrosine phosphorylation. Mechanistic studies reveal that CD4(+)CD25(+)CD127(low)Foxp3(+) Tregs produce IL-10, IL-4, and IL-13 and that these cytokines are the critical factors involved in the suppression of the proinflammatory cytokine response. In contrast, the Treg-mediated induction of CD206 is entirely cytokine-independent, whereas the up-regulation of CD163, CCL18, and phagocytosis are (partly) dependent on IL-10 but not on IL-4/IL-13. Together these data demonstrate a previously unrecognized function of CD4(+)CD25(+)Foxp3(+) Tregs, namely their ability to induce alternative activation of monocytes/macrophages. Moreover, the data suggest that the Treg-mediated induction of AAM partly involves a novel, cytokine-independent pathway. 相似文献
8.
A novel mutation in GMPPA in siblings with apparent intellectual disability,epilepsy, dysmorphism,and autonomic dysfunction 下载免费PDF全文
9.
目的制备和评价甘露糖修饰壳聚糖包衣乳酸-羟基乙酸共聚物(PLGA)纳米粒,考察其对巨噬细胞毒性和对巨噬摄取功能的影响。方法采用复乳法制备负载卵清蛋白(OVA)的PLGA纳米粒,并经甘露糖修饰壳聚糖包衣处理后用激光粒度测定仪测定该纳米粒的大小与ζ电位,透射电镜观察纳米粒的外观形态,BCA法测定OVA含量后计算载药量与释放度。负载异硫氰酸荧光素(FITC)标记的OVA纳米粒与巨噬细胞(RAW 264.7)共孵育,MTT法测定细胞存活率,荧光显微镜考察摄取程度。结果 OVA-PLGA纳米粒的大小和ζ电位均随壳聚糖包衣液浓度的增加而变大(P〈0.05),OVA载药量范围为7.2%~8.4%。壳聚糖与甘露糖修饰壳聚糖包衣FITC-OVA-PLGA纳米粒与RAW 264.7共孵育后,对细胞存活率的影响不大(P〉0.05),但可明显促进FITC-OVA-PLGA纳米粒的巨噬细胞摄取(P〈0.05)。结论初步建立了负载模型抗原的甘露糖修饰阳离子型纳米粒系统,这为体内抗原递呈细胞靶向性研究提供了依据。 相似文献
10.
《Arab Journal Of Gastroenterology》2022,23(4):241-245
Background and study aimAnti-Saccharomyces cerevisiae antibodies (ASCA) have been described in many autoimmune diseases (AIDs). Coronavirus disease 2019 (COVID-19) could trigger AIDs. This study aimed to determine the frequency of ASCA in patients with COVID-19.Patients and methodsThis study included 88 adult patients with severe COVID-19, 51 mild COVID-19, and 160 healthy blood donors. ASCA of isotype immunoglobulin (Ig)G and IgA were detected by enzyme-linked immunosorbent assay.ResultsThe frequency of ASCA (IgG or IgA) was significantly higher in patients with severe COVID-19 (21.6 % vs 3.7 %, p < 10?3) and in patients with mild COVID-19 than in the healthy controls (13.7 % vs 3.7 %, p = 0.03). ASCA-IgA was significantly more frequent in patients with severe COVID-19 than in healthy controls (15.9 % vs 0.6 %, p < 10?3). ASCA-IgG was significantly more frequent in patients with mild COVID-19 than in healthy controls (13.7 % vs 3.1 %, p = 0.02). ASCA (IgG or IgA) were more frequent in severe than in mild COVID-19, but the difference was not statistically significant (21.6 % vs 13.7 %). ASCA-IgA was significantly more frequent in patients with severe than those with mild COVID-19 (15.9 % vs 0 %, p = 0.003). The mean ASCA-IgG and ASCA-IgA levels were significantly higher in patients with severe COVID-19 than in healthy controls (5.8 U/mL ± 11.8 vs 2.3 U/mL ± 2.8, p < 10?3 and 9.2 U/mL ± 21.5 vs 3.4 U/mL ± 1.7, respectively, p < 10?3). The mean ASCA-IgG levels were significantly higher in patients with mild COVID-19 than in healthy controls (6.2 U/mL ± 12.9 vs 2.3 U/mL ± 2.8, p < 10?3). The mean ASCA-IgA levels were significantly higher in patients with severe than in those with mild COVID-19 (9.2 U/mL ± 21.5 vs 2.6 U/mL ± 1.2, p = 0.03).ConclusionASCA was more frequent in patients with COVID-19 than in healthy controls. 相似文献